
Poor Europeans live longer than rich Americans, study reveals stark contrast
Published in the
New England Journal of Medicine,
the study tracked nearly 74,000 individuals aged 50 to 85 across the US and 16 European countries from 2010 to 2022. Surprisingly, some of the poorest Europeans were found to outlive even the wealthiest Americans, revealing deep disparities tied to national healthcare systems and social structures.
Europe vs. US: Wealth doesn't guarantee longevity
Researchers divided Europe into three regions—northern and western, southern, and eastern—comparing survival rates to those in the United States.
The US had the highest overall death rate at 6.5 per 1,000 people, while northern and western Europe had a much lower rate of 2.9. Even more telling, wealthy Americans had lower survival rates than everyone in northern and western Europe and were only on par with the poorest in those regions.
This pattern persisted across multiple metrics. The poorest Americans died younger than their European counterparts, and the survival gap between America's rich and poor was the widest of any nation studied.
According to researchers, factors like income inequality, limited access to healthcare, and weaker social support structures in the US help explain this disturbing trend.
The role of welfare systems and social support
Experts say Europe's stronger welfare policies likely play a major role in these outcomes. Countries like the Netherlands, France, and Germany provide broader access to healthcare, affordable housing, and public support for aging populations.
Dr. Martin McKee, a professor of European public health, noted that robust social safety nets benefit not just the poor, but the middle class as well.
Europe's universal healthcare systems, along with preventive care programs, income support, elder care, and housing assistance, create a protective framework that sustains public health across all socioeconomic groups. These policies don't only improve outcomes for those at the bottom—they raise the baseline for everyone.
In contrast, the US approach—heavily reliant on employer-based insurance, private healthcare, and minimal government intervention—excludes millions and creates gaps even among those with stable incomes.
The study controlled for major risk factors such as gender, education, smoking habits, and chronic illnesses, which strengthens its conclusion that national policy—not just personal behavior—plays a pivotal role in longevity. However, it did not account for the influence of racial disparities or the ultra-wealthy 1%, which researchers say could further widen the inequality picture. Still, the core message remains stark: a society's collective investment in healthcare and social support directly impacts how long and well its people live.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
14 hours ago
- Economic Times
Cheaper cancer care therapy earns big bucks for pharma company
India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.


Time of India
15 hours ago
- Time of India
Cheaper cancer care therapy earns big bucks for pharma company
ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion."Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla , Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.

Hindustan Times
20 hours ago
- Hindustan Times
Smoke in New York: Canadian wildfires worsen air quality
The skies over New York turned hazy again on Saturday as smoke from Canada's wildfires drifted south, prompting state officials to issue a health advisory. The alert, covering New York City, Long Island, the Hudson Valley, and the Adirondacks, warns that the air is now 'unhealthy for sensitive groups.' Canada's wildfires are causing widespread air quality concerns in the U.S., with advisories issued for New York and surrounding areas. Pitts Stop Garage/via REUTERS (Pitts Stop Garage via REUTERS) Also Read: Michigan stabbing: Meet Derrick Perry, the brave shopper who stopped Walmart attacker Notice issued by DECD amid bad air quality The notice came from the state Department of Environmental Conservation and Department of Health, both posting the message on X. Anyone with breathing issues, especially kids and older adults, is being told to limit time outdoors. "DEC and @HealthNYGov have issued an air quality health advisory today, July 26, for Long Island, NYC Metro, Lower and Upper Hudson Valley, and Adirondacks due to smoke from wildfires in Canada. Air Quality Hotline: 1-800-535-1345," read the post. Wildfires across Canada are still burning out of control. Tens of thousands of residents have been forced to leave their homes. The smoke is crossing the border, turning much of the northern U.S. into a haze-filled zone. AQI climbs above 100 According to the BBC, State officials revealed that the air quality index is expected to top 100, with some areas pushing 135. Numbers like that mean the air can irritate lungs and trigger asthma or heart problems. Parts of New England are also dealing with the same conditions. The AQI is a simple scale: the higher the number, the worse the pollution. Anything over 100 is considered a health risk for vulnerable groups. These warnings have become all too familiar this summer. In mid-July, Chicago dealt with a similar alert as smoke rolled across the Midwest. Also Read: New Jersey weather radar: Flood, power outages hit NJ and New York amid NWS warnings Wildfires raise political concerns The smoke has even become a political issue. Earlier this month, six U.S. lawmakers sent a letter to Canada's ambassador, saying the haze was making life miserable for Americans trying to enjoy summer. Canada is currently fighting more than 550 active fires, with most centered in Manitoba. Around 6.1 million hectares - about 15 million acres - have already burned in the past year. In May and June, 30,000 people were evacuated in Saskatchewan and Manitoba after states of emergency were declared, according to the BBC. Experts say climate change is behind the worsening fire seasons. Canada is warming at roughly twice the global average, while its Arctic regions are heating up almost three times faster. FAQs Why is New York's air quality so bad right now? Because smoke from Canadian wildfires has drifted into the region. Which areas are under alert in New York? Long Island, NYC metro, Lower and Upper Hudson Valley, and the Adirondacks. How bad is the air quality index today? It's forecasted to be above 100, with some areas hitting 135. Are Canadian wildfires linked to climate change? Scientists say rising temperatures are making wildfire seasons longer and more intense. How many wildfires are burning in Canada? Authorities report more than 550 active fires, mostly in Manitoba.